These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1804595)

  • 1. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
    Schmid L; Jeschko M; Wilder-Smith C; Schafroth U; Thürlimann B; Pedrazzini A; Senn H
    Chemotherapy; 1991; 37(5):346-52. PubMed ID: 1804595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
    Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
    Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
    Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
    Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
    Liu CY; Wang FD
    Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients.
    Krcméry V; Koza I; Mardiak J; Fuchsberger P; Spánik S; Trupl J; Horníková M; Kusenda Z; Sufliarsky J; Svec J
    Chemotherapy; 1992; 38(1):74-6. PubMed ID: 1618007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication.
    Krcméry V; Danisovicová A; Drgona L; Spánik S; Fuchsberger P; Korec S; Svec J
    Neoplasma; 1993; 40(2):103-5. PubMed ID: 8350953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients.
    Nováková IR; Donnelly JP; de Pauw BE
    Ann Hematol; 1991 Oct; 63(4):195-200. PubMed ID: 1932297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin.
    Gibson J; Date L; Joshua DE; Young GA; Wilson A; Benn R; Benson W; Iland H; Vincent PC; Kronenberg H
    Aust N Z J Med; 1989 Oct; 19(5):417-25. PubMed ID: 2686610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia.
    Casali A; Ameglio F; Gionfra T; Tonachella R; Paoletti G; Gallo Curcio C
    Chemioterapia; 1987 Dec; 6(6):440-4. PubMed ID: 3325175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.
    Feliu J; Artal A; González Barón M; Berrocal A; Chacón I; García de Paredes ML; Espinosa E; Ordóñez A; Zamora P; Montero JM
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2816-20. PubMed ID: 1482151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
    Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
    Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospective and comparative study of 2 antibiotic therapy protocols in 66 febrile neutropenic patients. Ceftazidime-vancomycin versus ticarcillin-vancomycin-amikacin].
    Brion JP; Bru JP; Michallet M; Corron B; Fauconnier J
    Presse Med; 1988 Oct; 17(37):1964-7. PubMed ID: 2973597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases.
    Blanc C; Pollet JP; Bauters F
    Chemotherapy; 1991; 37(5):382-8. PubMed ID: 1804600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.